There appears to be growing understanding within the industry of...

There appears to be growing understanding within the industry of the unique benefits of RNA therapeutics, especially in the context of haploinsufficiency diseases, to which gene therapies are not as well suited @hottod

The CEO specifically mentioned the pivot by GSK to highlight an important shift in the field of precision medicine. In the article published in Fierce Biotech in February 2023 titled 'It's the right call': GSK expresses no regrets on abandoning cell therapy as oligo strategy heats up, we discover that some Big Pharma players are heading into our sand pit.

And what a remarkable decision by GSK who decided to end their investment in cell and gene therapy and focus instead on employing oligonucleotides to reach genetically validated targets. There is that term that our CEO stressed in his presentation - genetically validated targets. In fact it features three times;

1. Slide 10 - selecting genetically validated (monogenic) targets
2. Slide 13 - genetic validation of the target remains the single most important consideration informing success in the clinic
3. Slide 13 - PYC pursues drug targets with the highest degree of genetic validation

Its a small sand pit with players like Ionis, Alynlam and Wave Life Sciences. GSK have teamed up with Wave but in our own corner PYC are equipped with a special tool; a delivery platform that overcomes the primary challenge for precision therapies of getting enough of the RNA drug into the cell in order to reach its target. Our corner could become very busy very quickly particularly as the first cohort is even now busily prepping.

Long time readers and investors will know that PYC have also done a pivot or two but it does appear that we have ended up in the right place at the right time.